title: Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.
abstract: OBJECTIVE
  Many data regarding omeprazole-, lanzoprazole- and pantoprazole-based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C)and tinidazole (T) in H. pylori eradication.
  
  
  METHODS
  Ninety-four H. pylori-positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one-week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy.
  
  
  RESULTS
  Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B (P-value not significant). Minor side-effects were reported in 4.2% of group A and 6.4% of group B patients.
  
  
  CONCLUSIONS
  Rabeprazole showed good efficacy and tolerability in one-week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage.
authors.affiliation: Department of Clinical Science, University of Parma, Parma, Italy. francesco.dimario@unipr.it
authors.forename: Francesco Di
authors.initials: FD
authors.lastname: Mario
authors.forename: Nadia
authors.initials: N
authors.lastname: Dal Bo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Aragona
authors.forename: Ali M
authors.initials: AM
authors.lastname: Moussa
authors.forename: Veronica
authors.initials: V
authors.lastname: Iori
authors.forename: Giulia M
authors.initials: GM
authors.lastname: Cavestro
authors.forename: Alberto
authors.initials: A
authors.lastname: Pilotto
authors.forename: Gioacchino
authors.initials: G
authors.lastname: Leandro
authors.forename: Marilisa
authors.initials: M
authors.lastname: Franceschi
authors.forename: Massimo
authors.initials: M
authors.lastname: Rugge
authors.forename: Angelo
authors.initials: A
authors.lastname: Franze
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D000994:Antitrichomonal Agents / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage*; D001944:Breath Tests; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole; D014011:Tinidazole / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000994:Antitrichomonal Agents; D001562:Benzimidazoles; D014011:Tinidazole; D064750:Rabeprazole; D017291:Clarithromycin; D009853:Omeprazole